BiotechTube
Micro Interventional Devices

Micro Interventional Devices

New Hope, United States· Est.
microinterventional.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

Micro Interventional Devices is a private, pre-revenue medical device company developing a disruptive platform for transcatheter cardiac repair. Its core technology is the proprietary PolyCor anchoring system, which enables percutaneous annuloplasty procedures for treating tricuspid and mitral regurgitation. The company's lead product, the MIA-T system for tricuspid valve repair, has FDA Breakthrough Device designation and is in clinical trials, while the mitral system, MIA-M, anticipates first-in-human use in 2024. MID aims to transform structural heart disease treatment by offering surgical efficacy with the safety of a catheter-based approach.

Cardiovascular

Technology Platform

Proprietary Transcatheter Cardiac Repair (TCR) platform featuring the PolyCor polymeric anchor system for soft-tissue fixation, delivered via a 12F catheter to perform percutaneous annuloplasty on a beating heart without cardiopulmonary bypass.

Funding History

3
Total raised:$60M
Series C$30M
Series B$20M
Series A$10M

Opportunities

The tricuspid valve repair market represents a large, underserved patient population with high unmet need, creating a significant greenfield opportunity for a first-mover like MID with its Breakthrough designated MIA-T system.
Furthermore, the company's versatile PolyCor platform allows for expansion into the larger mitral valve market and potentially other structural heart applications, offering a pathway for substantial growth.

Risk Factors

The company faces significant clinical and regulatory risk, as its entire value depends on successful trial outcomes and FDA approval for its investigational devices.
It also operates in an intensely competitive landscape against well-capitalized large medtech firms and other startups, posing a major challenge to future market share and commercialization.

Competitive Landscape

MID competes in the high-growth transcatheter valve repair space, facing established giants like Abbott (MitraClip, TriClip) and Edwards Lifesciences in mitral, and a rapidly evolving field of startups (e.g., Cardiovalve, 4C Medical) in tricuspid. Its annuloplasty-based approach differentiates it from leaflet-based repair devices, but it must prove superior or complementary clinical utility to gain traction.

More companies in Digital Health & Biotech SaaS →More companies in United States →